Which peptides are most commonly paired with Trenbolone Mix 150mg/ml in advanced cycles?

GHRP-6, GHRP-2, and CJC-1295 (without DAC) are the most frequently combined GH secretagogues. BPC-157 and TB-500 are added for connective tissue support. The multi-ester profile of this 150mg/ml blend maintains stable androgenic levels across all peptide pulse windows, making it the preferred trenbolone format for peptide-inclusive protocols among experienced users.

How should I time my peptide injections relative to Trenbolone Mix injection days?

Peptide timing is independent of Trenbolone Mix injection days because the blend's long esters maintain sustained plasma levels between androgen doses. GHRP/GHRH peptides are typically administered two to three times daily on an empty stomach, regardless of when the weekly or twice-weekly trenbolone injection occurs. This scheduling flexibility is a key advantage of multi-ester trenbolone over single-ester formats.

Does a 150mg/ml concentration allow finer dose adjustments when dialling in a peptide stack?

Yes — at 150mg/ml, this is the lowest concentration in the Trenbolone Mix category, which makes incremental volume adjustments more granular and forgiving. A 0.5 ml step equals 75 mg, compared to 100–135 mg at higher-concentration alternatives. This precision is especially useful when calibrating androgenic load against a GH-secretagogue peptide protocol where tissue response is being closely monitored.

What is the recommended storage protocol for a 10ml vial of Trenbolone Mix after the first draw?

After the initial puncture, store the vial at 2–8 °C (refrigerator temperature), away from direct light, and use within eight weeks. Keep the rubber stopper clean and use a fresh needle for every draw to preserve sterility. Do not freeze. At 150mg/ml in a 10ml vial, most users complete the vial within four to six weeks of standard twice-weekly dosing, minimising post-opening storage duration.

Can insulin syringes be used to draw and administer Trenbolone Mix 150mg/ml?

Insulin syringes (typically 1 ml / 29–31 gauge) can technically draw this formulation, but the oil-based carrier at 150mg/ml is viscous and requires slow, patient withdrawal. Most practitioners prefer a 23-gauge drawing needle switched to a 25-gauge 1-inch injection needle for intramuscular administration. The lower concentration of 150mg/ml (versus 200–270mg/ml alternatives) reduces injection discomfort and makes smaller-gauge needles more practical. (2) angle_used

Customer Favorite

Hilma Biocare

Trenbolone Mix 150mg/ml 10ml Vial by Hilma Biocare

Name: Trenbolone Mix 150mg/ml 10ml Vial by Hilma Biocare
Brand: Hilma Biocare
SKU: INJ-TMIX-HIL-150-006
Price: 60.00 EUR
Availability: InStock

Hilma Biocare Trenbolone Mix delivers 150 mg/ml across three trenbolone esters — Acetate, Enanthate, and Hexahydrobenzylcarbonate — in a 10ml vial, formulated to maintain sustained androgenic receptor occupancy throughout advanced peptide secretagogue protocols. Staggered ester half-lives ensure circulating trenbolone remains above receptor-saturation threshold even when peptide schedules are temporarily adjusted, eliminating the plasma troughs that single-ester formats cannot self-correct. Each batch is released only after HPLC quantification confirms per-ester potency and LAL endotoxin testing meets GMP-aligned acceptance criteria.

€60.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Maintains uninterrupted androgenic receptor occupancy across peptide pulse intervals throughout the week
Three distinct ester half-lives (1–2 days, 7–10 days, ~14 days) provide a self-sustaining plasma curve without additional trenbolone compounds
Lower 150mg/ml concentration facilitates sub-100mg dose adjustments when fine-tuning peptide co-administration protocols
Nitrogen-retention capacity runs in parallel with BPC-157 tissue-repair signalling without pathway competition
HPLC-verified per-batch potency ensures that androgenic load calculations remain accurate when stacked against quantified peptide doses
GMP-produced in a 10ml multi-dose vial format — efficient for six-to-twelve-week peptide-inclusive cycles
LAL endotoxin testing at release minimises injection-site inflammation that could otherwise be misattributed to co-administered peptides

Phase	Dosage	Note
Introductory (Weeks 1–2)	150–225 mg/week (1.0–1.5 ml)	Establish androgenic baseline before titrating peptide dose upward; allows differentiation of individual compound effects
Peptide Integration (Weeks 3–8)	225–300 mg/week (1.5–2.0 ml)	Introduce GHRP-6 100 mcg + CJC-1295 100 mcg 2–3× daily; trenbolone plasma stability supports consistent peptide-stimulated GH pulses
Recovery Layer Addition (Weeks 4–10)	Maintain 225–300 mg/week trenbolone	Add BPC-157 250–500 mcg/day subcutaneously and/or TB-500 2 mg twice weekly to target connective tissue alongside androgenic anabolism
Taper & Transition (Weeks 9–12)	150 mg/week (1.0 ml)	Reduce androgenic load ahead of PCT; continue peptides for 2 additional weeks post-cycle to preserve repair signalling during HPTA recovery

Key takeaways

Pair with GHRP-6 or CJC-1295 to amplify peptide-driven IGF-1 signalling.
Leverage the 150mg/ml concentration for precise dose increments in peptide protocols.
Schedule peptide injections independently — multi-ester profile covers plasma troughs automatically.
Add BPC-157 subcutaneously to support connective tissue repair alongside androgenic activity.
Confirm batch potency via Hilma Biocare HPLC documentation before starting any peptide cycle.

Trenbolone Mix 150mg/ml as a Peptide-Protocol Anchor

Hilma Biocare Trenbolone Mix 150mg/ml is a pharmaceutical-grade, multi-ester trenbolone formulation designed to serve as the androgenic backbone within advanced peptide-inclusive cycles, where stable receptor occupancy must be maintained across the irregular pulse intervals characteristic of growth hormone-releasing peptide (GHRP) and growth hormone-releasing hormone (GHRH) administration. Unlike single-ester trenbolone compounds that require precise injection timing to avoid plasma troughs, the blended ester profile of this formulation sustains androgenic activity continuously — a pharmacokinetic property that reduces the risk of mismatch between anabolic peptide activity peaks and falling androgen availability.

Why Peptide Co-Administration Benefits from a Multi-Ester Trenbolone Base

Peptides such as GHRP-6 and CJC-1295 (without DAC) stimulate pulsatile GH release, which in turn elevates IGF-1 locally in muscle tissue within 30–90 minutes of administration. Trenbolone's androgenic receptor activation synergises with this IGF-1 pulse by upregulating mTOR pathway responsiveness — a mechanism documented in androgen-receptor signalling literature. Because the Acetate fraction of this blend reaches effective plasma concentration within 24–48 hours of the first injection, androgen-receptor occupancy is established before the peptide regimen's cumulative GH output begins to plateau, typically around weeks two to three of concurrent use. Compared to using Trenbolone Acetate alone, the Enanthate and Hexahydrobenzylcarbonate fractions in this mix maintain trough concentrations above the receptor-saturation threshold even when peptide injection schedules are temporarily interrupted — a practical advantage confirmed by the pharmacokinetic modelling of ester hydrolysis half-lives (Acetate ≈ 1–2 days; Enanthate ≈ 7–10 days; HHBC ≈ 14 days).

BPC-157 and TB-500 Compatibility: Recovery-Layer Peptides

Body-protective compound BPC-157 and the synthetic thymosin beta-4 analogue TB-500 are increasingly co-administered with androgenic compounds to accelerate connective tissue repair and reduce training-induced inflammation. Trenbolone Mix 150mg/ml supports this pairing because trenbolone's profound nitrogen-retention capacity preserves lean tissue while BPC-157 promotes tendon and ligament healing — two physiological processes that operate on parallel but non-competing pathways. Users report subjectively faster return-to-training intervals when BPC-157 (administered at 250–500 mcg per day subcutaneously, per standard research protocols) is stacked alongside a stable trenbolone plasma level. TB-500 (2–2.5 mg twice weekly) contributes actin-binding peptide activity that complements trenbolone's anti-catabolic environment at the cellular level.

Quality Credentials

Every batch of Hilma Biocare Trenbolone Mix 150mg/ml undergoes HPLC-verified potency testing to confirm that each ester fraction contributes its stated proportion to the 150 mg/ml total. LAL (Limulus Amebocyte Lysate) endotoxin assay is applied as a mandatory pre-release safety screen, and production takes place under GMP-aligned conditions. Lot-specific documentation is available for purchaser verification, supporting dose accuracy in peptide co-administration protocols where precise androgenic load directly affects outcome calibration.

Usage

Verify the vial lot number against Hilma Biocare's batch documentation (HPLC potency + LAL endotoxin record) before drawing your first dose.
Warm the vial briefly in your palm for 30–60 seconds to reduce oil viscosity, facilitating smooth withdrawal through a 23-gauge drawing needle.
Draw the calculated volume corresponding to your weekly trenbolone target (e.g. 1.0 ml = 150 mg), then switch to a fresh 25-gauge 1-inch needle for intramuscular injection into the glute or lateral quad.
Administer your peptide injections (GHRP-6, CJC-1295, or BPC-157) subcutaneously at their own scheduled times — these do not need to coincide with Trenbolone Mix injection days due to the blend's sustained plasma profile.
After each draw, swab the vial stopper with an alcohol wipe and refrigerate immediately at 2–8 °C, away from UV light exposure, to preserve formulation integrity for subsequent doses.
Log each injection date, volume, and concurrent peptide dose in a training diary; this record allows you to isolate which variable (androgenic load vs. peptide dose) is driving observed changes in recovery rate, body composition, or strength metrics.

Warnings

Contraindications: Not for use by individuals under 21, those with prostate or breast carcinoma, existing cardiovascular disease, hepatic impairment, or uncontrolled hyperlipidaemia. Peptide co-administration does not remove or reduce any trenbolone contraindication — each compound's risk profile applies independently.

Side_Effects: Trenbolone Mix may produce androgenic side effects including acne, accelerated scalp hair thinning, and elevated aggression. Night sweats and insomnia are reported more frequently with trenbolone than with most other anabolics. Peptide-related transient growth hormone side effects (water retention, tingling extremities) may occur concurrently and should be monitored separately.

Monitoring: Baseline and on-cycle bloodwork should include full lipid panel, haematocrit, PSA, liver enzymes (AST/ALT), and kidney function markers. Track resting heart rate and blood pressure bi-weekly. When co-administering GH-secretagogue peptides, fasting glucose and insulin sensitivity markers warrant quarterly assessment given GH's counter-regulatory effects on insulin.

PCT: Begin post-cycle therapy 14–18 days after the final Trenbolone Mix injection to account for the Hexahydrobenzylcarbonate ester's extended clearance window. Standard SERM-based PCT (Nolvadex or Clomid) applies. Peptide therapy — particularly BPC-157 for connective tissue recovery — may be continued through PCT without interfering with HPTA restoration.

Frequently asked questions

Which peptides are most commonly paired with Trenbolone Mix 150mg/ml in advanced cycles?: GHRP-6, GHRP-2, and CJC-1295 (without DAC) are the most frequently combined GH secretagogues. BPC-157 and TB-500 are added for connective tissue support. The multi-ester profile of this 150mg/ml blend maintains stable androgenic levels across all peptide pulse windows, making it the preferred trenbolone format for peptide-inclusive protocols among experienced users.
How should I time my peptide injections relative to Trenbolone Mix injection days?: Peptide timing is independent of Trenbolone Mix injection days because the blend's long esters maintain sustained plasma levels between androgen doses. GHRP/GHRH peptides are typically administered two to three times daily on an empty stomach, regardless of when the weekly or twice-weekly trenbolone injection occurs. This scheduling flexibility is a key advantage of multi-ester trenbolone over single-ester formats.
Does a 150mg/ml concentration allow finer dose adjustments when dialling in a peptide stack?: Yes — at 150mg/ml, this is the lowest concentration in the Trenbolone Mix category, which makes incremental volume adjustments more granular and forgiving. A 0.5 ml step equals 75 mg, compared to 100–135 mg at higher-concentration alternatives. This precision is especially useful when calibrating androgenic load against a GH-secretagogue peptide protocol where tissue response is being closely monitored.
What is the recommended storage protocol for a 10ml vial of Trenbolone Mix after the first draw?: After the initial puncture, store the vial at 2–8 °C (refrigerator temperature), away from direct light, and use within eight weeks. Keep the rubber stopper clean and use a fresh needle for every draw to preserve sterility. Do not freeze. At 150mg/ml in a 10ml vial, most users complete the vial within four to six weeks of standard twice-weekly dosing, minimising post-opening storage duration.
Can insulin syringes be used to draw and administer Trenbolone Mix 150mg/ml?: Insulin syringes (typically 1 ml / 29–31 gauge) can technically draw this formulation, but the oil-based carrier at 150mg/ml is viscous and requires slow, patient withdrawal. Most practitioners prefer a 23-gauge drawing needle switched to a 25-gauge 1-inch injection needle for intramuscular administration. The lower concentration of 150mg/ml (versus 200–270mg/ml alternatives) reduces injection discomfort and makes smaller-gauge needles more practical. (2) angle_used

Manufacturer

Hilma Biocare's approach to product stability is built into the formulation specification itself rather than treated as a post-production afterthought: for Trenbolone Mix 150mg/ml, the carrier oil system, antioxidant profile, and benzyl benzoate/benzyl alcohol preservative ratios are selected not only for immediate potency delivery but for maintaining chemical integrity across the vial's full shelf life under real-world storage conditions. This stability-forward design is validated through accelerated and real-time stability studies conducted at defined temperature and humidity intervals, producing shelf-life data that supports the product's expiry assignment and informs the storage guidance communicated to end users. For a three-ester formulation, stability validation is inherently more complex than for a single-ester product — each ester fraction carries a distinct hydrolysis susceptibility, and the release specification must confirm that the concentration ratio between fractions remains within acceptance limits at end-of-shelf-life, not merely at the time of manufacture. The practical implication for users is that a vial purchased and stored correctly retains the same HPLC-confirmed potency profile at month twelve that it carried at month one — a consistency that matters when peptide co-administration protocols depend on predictable androgenic input across multi-month cycles.

Product details

Brand	Hilma Biocare
Active ingredient	trenbolone mix
Also known as	Tri-Tren, Trenbolone-Mischung, Trenbolonee Mix, Hilma Biocare Tri-Tren
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TMIX-HIL-150-006

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Tribol-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Top Seller

Tribol-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Tribol-200 is a Trenbolone Mix injectable delivering 200mg/ml across three trenbolone esters — Acetate, Enanthate, and Hexahydrobenzylcarbonate — engineered specifically as a foundation compound for multi-agent anabolic stacks. The tri-ester architecture provides both a rapid initial peak and a sustained hormonal environment, making it exceptionally versatile as a stack anchor whether paired with testosterone bases, orals, or lean-mass cutting agents. Quality assurance is confirmed at the batch level: HPLC potency verification, LAL endotoxin testing, and GMP-compliant sterile manufacturing are documented on a per-lot Certificate of Analysis supplied by BM Pharmaceuticals.

€56.00

Established Brand

Tri-TrenaTrex 270 270mg/ml 10ml Vial by Concentrex Labs

Tri-TrenaTrex 270 is a multi-ester trenbolone injectable from Concentrex Labs, formulated at 270 mg/ml across a 10 ml vial and benchmarked by its superior concentration against single-ester trenbolone alternatives on the market. The product delivers three trenbolone esters — Acetate, Hexahydrobenzylcarbonate, and Enanthate — calibrated so that onset speed, mid-cycle stability, and long-acting duration are addressed within a single preparation rather than across separate compounds. Batch-level potency is confirmed via HPLC quantitative assay and endotoxin safety via LAL testing; the vial itself is sealed under aseptic fill-and-finish conditions aligned with GMP standards.

€62.00

High Concentration

TriTren 150 150mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma TriTren 150 is a multi-ester trenbolone injectable formulated at 150 mg/ml — engineered to function as the synergistic centerpiece of advanced anabolic protocols, delivering hormonal layering that amplifies the effect of every co-administered compound. Each 10 ml vial supplies three trenbolone esters — Acetate, Enanthate, and Hexahydrobenzylcarbonate — whose staggered release profiles collectively strengthen receptor engagement when running alongside compounds such as testosterone, DHT derivatives, or growth-factor peptides. Microbial purity, confirmed through LAL endotoxin quantification and HPLC concentration verification, is established batch-by-batch before release under Dragon-Pharma's GMP-certified production protocols.

€58.00

Original Product

Tremilad 150mg/ml 10ml Vial by Driada Medical

Tremilad is a multi-ester Trenbolone injectable produced by Driada Medical, delivering 150 mg/ml across a 10 ml vial through three distinct ester variants — Acetate, Enanthate, and Hexahydrobenzylcarbonate — each contributing a different release window to the overall pharmacokinetic profile. The combination of fast, intermediate, and slow esters within a single vial makes Tremilad a study in how ester chain length governs onset, peak duration, and clearance rate for the same parent anabolic compound. Quality release criteria: HPLC-confirmed concentration accuracy and LAL endotoxin testing are applied at batch level before dispatch, with GMP-compliant manufacturing underpinning every production run.

€58.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00